Reposted by Meghan Morrissey
Congratulations @jcstark.bsky.social and the team, antibody-lectin chimeras (AbLecs), a new modality for cancer immune therapy, now published @natbiotech.nature.com. These bispecifics can block glyco-immune checkpoint receptor ligands directly at the immune synapse/activate immune effector functions